A study of Sofosbuvir and Ribavirin in patients with Auckland Clinical Studies Limited 13/NTA/162 Approve Genotype 1 or 3 Chronic Prof Edward Gane Dr Richard Robson Intervention Taylor, CCST Ltd Hepatitis C and Renal Insufficiency. A to investigate a new drug Sofosbuvir when used with Ribavirin for 16 or 24 Auckland District Health weeks or when used with 13/NTA/165 Approve Professor Ed Gane Board,CCDHB,cdhb,Health Intervention Ribavirin and pegylated Research South,Jan Adams, COO interferon for 12 weeks in Patients with chronic Hepatitis infection Associate Professor 13/NTA/166 Approve PI 13-05 Dr Andrew Hill Auckland District Health Board Intervention Andrew Holden Carol Veale,Dr Samantha Everitt PT003008 - A 28-week (CMDHB),Jan Adams, COO,Jim 13/NTA/167 Approve safety extension study from Dr Dean Quinn Intervention Reid,Prof Richard Stubbs, P3 PT003006 Research 13/NTA/168 Approve WHiP Mr Lindsay McTavish CCDHB Intervention 13/NTA/170 Approve Cervical Screening with HPV Dr Mee Ling Yeong Intervention An Efficacy and Safety of MK-8931 in subjects with amnestic Mild Cognitive Auckland Clinical Studies 13/NTA/171 Approve Dr Gilchrist Dr Jane Walton Intervention Impairment due to Limited,CGM Research Trust Alzheimer’s Disease (Prodromal AD) Phase I study of selenium in 13/NTA/172 Approve Dr Michael Jameson Intervention cancer patients A of intravenous Alpha1-Proteinase inhibitor Carol Veale,Jan Adams, COO,NZ 13/NTA/173 Approve to assess the safety and Dr Jeffrey Garrett Dr Michael Epton Intervention Respiratory & Sleep Institute effectiveness in participants with Pulmonary Emphysema POINT: Platlet Oriented Professor Alan 13/NTA/19 Approve Inhibition in TIA and minor Auckland District Health Board Intervention Barber stroke.
13/NTA/162 Approve A study of Sofosbuvir and Ribavirin in patients with Genotype 1 or 3 Chronic Hepatitis C and Renal Insufficiency. Prof Edward Gane Dr Richard Robson Auckland Clinical Studies Limited Taylor, CCST Ltd Intervention 13/NTA/165 Approve A to investigate a new drug Sofosbuvir when used with Ribavirin for 16 or 24 weeks or when used with Ribavirin and pegylated interferon for 12 weeks in Patients with chronic Hepatitis infection Professor Ed Gane Auckland District Health Board,CCDHB,cdhb,Health Research South,Jan Adams, COO Intervention 13/NTA/166 Approve PI 13-05 Associate Professor Andrew Holden Dr Andrew Hill Auckland District Health Board Intervention 13/NTA/167 Approve PT003008 - A 28-week safety extension study from PT003006 Dr Dean Quinn Carol Veale,Dr Samantha Everitt (CMDHB),Jan Adams, COO,Jim Reid,Prof Richard Stubbs, P3 Research Intervention 13/NTA/168 Approve WHiP Mr Lindsay McTavish CCDHB Intervention 13/NTA/170 Approve Cervical Screening with HPV Dr Mee Ling Yeong Intervention 13/NTA/171 Approve An Efficacy and Safety of MK-8931 in subjects with amnestic Mild Cognitive Impairment due to Alzheimer’s Disease (Prodromal AD) Dr Gilchrist Dr Jane Walton Auckland Clinical Studies Limited,CGM Research Trust Intervention 13/NTA/172 Approve Phase I study of selenium in cancer patients Dr Michael Jameson Intervention 13/NTA/173 Approve A of intravenous Alpha1-Proteinase inhibitor to assess the safety and effectiveness in participants with Pulmonary Emphysema Dr Jeffrey Garrett Dr Michael Epton Carol Veale,Jan Adams, COO,NZ Respiratory & Sleep Institute Intervention 13/NTA/19 Approve POINT: Platlet Oriented Inhibition in TIA and minor stroke. Professor Alan Barber Auckland District Health Board Intervention
northern-a-ethics-committee-annual-report-2013.docx